Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IKS04
- Development stage
- Phase 1
- Lead developer
- Iksuda Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
IKS04 is an investigational antibody-drug conjugate (ADC) developed for the treatment of gastrointestinal cancers, particularly solid tumors such as colon adenocarcinomas. It consists of a humanized anti-CA242 (CanAg) monoclonal IgG1 antibody site-specifically conjugated to a highly potent DNA cross-linking payload—a PBD (pyrrolobenzodiazepine) prodrug—via a β-glucuronide linker. This design enables tumor-selective activation and release of the cytotoxic payload by beta-glucuronidase, an enzyme overexpressed in cancer cell lysosomes. The ADC is characterized as "ultra-low DAR" (drug-to-antibody ratio), aiming to maximize therapeutic index and minimize off-target toxicity. Preclinical studies have shown strong efficacy in GI tumor models. The drug is currently in late preclinical development with IND submission anticipated by 2025[1][2][3][7].
- Other names
- CA242-ADCCA-242-ADCCA 242-ADCCanAg-ADC
02
Targets
CanAg (CA242/CanAg glycoform of MUC1)
Beyond the preview
Go deeper on IKS04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IKS04.